您的位置: 首页 > 农业专利 > 详情页

TRAITEMENT ANTICANCÉREUX À DOUBLE CIBLAGE DE CD47 ET DE R-EGF
专利权人:
The Board of Trustees of the Leland Stanford Junior University
发明人:
申请号:
EP16873852.4
公开号:
EP3386545A2
申请日:
2016.12.08
申请国别(地区):
EP
年份:
2018
代理人:
摘要:
Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充